You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

~ Buy the ELUCIREM (gadopiclenol) Drug Profile, 2024 PDF Report in the Report Store ~

ELUCIREM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Elucirem, and when can generic versions of Elucirem launch?

Elucirem is a drug marketed by Guerbet and is included in one NDA. There are three patents protecting this drug.

This drug has ninety patent family members in twenty-six countries.

The generic ingredient in ELUCIREM is gadopiclenol. Two suppliers are listed for this compound. Additional details are available on the gadopiclenol profile page.

DrugPatentWatch® Generic Entry Outlook for Elucirem

Elucirem will be eligible for patent challenges on September 21, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 21, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for ELUCIREM
International Patents:90
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 4
Clinical Trials: 1
Patent Applications: 2
Drug Prices: Drug price information for ELUCIREM
What excipients (inactive ingredients) are in ELUCIREM?ELUCIREM excipients list
DailyMed Link:ELUCIREM at DailyMed
Drug patent expirations by year for ELUCIREM
Drug Prices for ELUCIREM

See drug prices for ELUCIREM

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ELUCIREM
Generic Entry Date for ELUCIREM*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ELUCIREM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GuerbetPhase 2

See all ELUCIREM clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ELUCIREM

US Patents and Regulatory Information for ELUCIREM

ELUCIREM is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ELUCIREM is ⤷  Try a Trial.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ELUCIREM

Gadolinium bearing PCTA-based contrast agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting ELUCIREM

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet ELUCIREM gadopiclenol SOLUTION;INTRAVENOUS 216986-007 Sep 21, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Guerbet ELUCIREM gadopiclenol SOLUTION;INTRAVENOUS 216986-001 Sep 21, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Guerbet ELUCIREM gadopiclenol SOLUTION;INTRAVENOUS 216986-005 Sep 21, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ELUCIREM

See the table below for patents covering ELUCIREM around the world.

Country Patent Number Title Estimated Expiration
Spain 2841070 ⤷  Try a Trial
China 113735854 钆和基于非对映异构体富集的PCTA的螯合配体的络合物及其制备和纯化方法 (Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process) ⤷  Try a Trial
Poland 3687994 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ELUCIREM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1931673 301259 Netherlands ⤷  Try a Trial PRODUCT NAME: GADOPICLENOL; REGISTRATION NO/DATE: EU/1/23/1772 20231208
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.